Pfizer, Moderna and COVID-19
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Investor's Business Daily on MSN2d
Why Moderna Stock Has Surged 15% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...
Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. Moderna (NasdaqGS:MRNA) recently experienced a notable 10% ...
Bullish option flow detected in Moderna (MRNA) with 25,737 calls trading, 1.2x expected, and implied vol increasing almost 4 points to 82.07%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback